Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-363P is a pseudogene copy of the U6 small nuclear RNA gene. U6 snRNA itself is an essential component of the spliceosome, the cellular machinery that removes introns from pre-mRNA[3][5]. Pseudogenes like RNU6-363P are DNA sequences similar to known genes but are typically nonfunctional due to mutations, lack of regulatory elements, or because they are not transcribed into functional RNA or protein. Though some pseudogenes can act as regulatory elements (such as miRNA decoys or competitive endogenous RNAs)[4], there is no current evidence that RNU6-363P has such a role. Additionally, "RNA, U6 small nuclear 363, pseudogene" is not a drug target or a molecule with direct cellular or pharmacological action, and therefore does not fall into conventional molecular classifications used for therapeutic targets such as "receptor," "enzyme," or "transport." This entry is primarily notable as a non-functional genomic element, and is not considered a receptor or other functional molecular target in drug discovery or therapeutic contexts, hence is_incorrect: true for purposes of most molecular targeting databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 363, pseudogene (RNU6-363P).